GAMMA Investing LLC Has $1.68 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

GAMMA Investing LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 19.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,228 shares of the biopharmaceutical company’s stock after acquiring an additional 2,955 shares during the quarter. GAMMA Investing LLC’s holdings in Gilead Sciences were worth $1,684,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Lantz Financial LLC raised its holdings in Gilead Sciences by 3.5% in the 2nd quarter. Lantz Financial LLC now owns 24,920 shares of the biopharmaceutical company’s stock valued at $1,710,000 after buying an additional 840 shares during the last quarter. Simon Quick Advisors LLC increased its stake in shares of Gilead Sciences by 11.3% in the second quarter. Simon Quick Advisors LLC now owns 3,390 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 343 shares during the period. Larson Financial Group LLC lifted its stake in shares of Gilead Sciences by 192.8% in the second quarter. Larson Financial Group LLC now owns 4,371 shares of the biopharmaceutical company’s stock worth $300,000 after acquiring an additional 2,878 shares during the period. Belpointe Asset Management LLC increased its position in Gilead Sciences by 19.4% during the 2nd quarter. Belpointe Asset Management LLC now owns 13,143 shares of the biopharmaceutical company’s stock valued at $902,000 after purchasing an additional 2,137 shares during the period. Finally, Nicholas Hoffman & Company LLC. bought a new position in Gilead Sciences during the 2nd quarter worth approximately $301,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. The trade was a 67.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew D. Dickinson sold 8,500 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $91.96, for a total value of $781,660.00. Following the completion of the sale, the chief financial officer now owns 132,373 shares in the company, valued at $12,173,021.08. This trade represents a 6.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 453,734 shares of company stock valued at $41,902,086 over the last three months. Company insiders own 0.29% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the subject of several recent analyst reports. Royal Bank of Canada reiterated a “sector perform” rating and set a $84.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Wells Fargo & Company lifted their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Barclays raised their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 7th. Finally, Sanford C. Bernstein initiated coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price on the stock. Twelve analysts have rated the stock with a hold rating, twelve have assigned a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $96.43.

Gilead Sciences Trading Down 0.5 %

Shares of GILD stock opened at $91.41 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm has a market cap of $113.92 billion, a P/E ratio of 1,015.67, a PEG ratio of 2.38 and a beta of 0.18. The company has a 50 day moving average of $91.76 and a 200-day moving average of $82.22. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same quarter last year, the business earned $2.29 earnings per share. The company’s quarterly revenue was up 7.0% on a year-over-year basis. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were given a dividend of $0.77 per share. The ex-dividend date was Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.37%. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.